Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

• Upcoming R&D sessions on oncology, Dupixent^® (dupilumab), and nirsevimab
• Initial session focused on brain-penetrant BTKi ‘168 Phase 2 data
• Virtual R&D day event on June 23 to showcase Sanofi’s industry leading platforms, unique capabilities, and innovative medicines to fuel future growth

PARIS – May 18, 2020 – Sanofi announced today that it is hosting a series of interactive webcast events highlighting key priority pipeline programs that will conclude with the company’s virtual R&D day event on Tuesday, June 23. The five-part webcast series was initiated with the presentation of the Phase 2 results and Sanofi’s development strategy for its brain-penetrant BTKi’168 for multiple sclerosis in April. Upcoming sessions will discuss Sanofi’s oncology strategy, line extension plans for Dupixent^® (dupilumab), and nirsevimab, the first time a monoclonal antibody potentially offers a population-based solution to prevent respiratory syncytial virus (RSV) for all infants.

“Over the coming weeks, we look forward to sharing the tremendous progress we’ve made in advancing our priority molecules and building a sustainable R&D engine,” said John Reed, Global Head of Research and Development at Sanofi.  “With a great team, deep therapeutic area expertise and an expanding toolbox of therapeutic platforms, Sanofi is poised to discover the next generation of life-changing medicines.”

Upcoming events

Oncology Strategy and ASCO R&D Investor Event

June 2, 2020 - 4:00 pm CET / 10 am ET (1.5 hours)

Dupixent R&D Investor Event

June 11, 2020 - 3:00 pm CET / 9:00 am ET (1.5 hours)

Nirsevimab R&D Investor Event

Date to follow - 3:00 pm CET / 9:00 am ET (1.5 hours)

Virtual R&D Day Event

June 23, 2020 - 3:00 pm CET / 9:00 am ET (2.5 hours)

Additional information about these upcoming events can be found at https://www.sanofi.com/en/investors